Private insurers decline to cover Biogen's new Alzheimer's drug in escalating standoff — report

As the fallout continues from the FDA’s controversial approval of Biogen’s new Alzheimer’s drug Aduhelm, some insurers are reportedly unwilling to cover the high costs associated with the drug.